Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evgen Pursues Pharmaceutical Development of Sulforadex - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Evgen Pursues Pharmaceutical Development of Sulforadex

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Having recently secured substantial investment from a U.K. venture capital syndicate, Evgen Limited has exercised its option with Lalilab, Durham, NC, and PharmAgra Labs, Brevard, NC, to enter a global, exclusive license agreement to develop Sulforadex as an oral pharmaceutical. Sulforadex has demonstrated potential in the prevention of prostate cancer and other cancers, according to the companies. Lalilab and PharmAgra retain the rights to develop the patented stabilized sulforaphane technology for topical applications, focusing on skin disease therapeutics and cosmetics.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters